US2015352263A1PendingUtilityA1

Medical device with coating that promotes endothelial cell adherence

61
Assignee: ORBUSNEICH MEDICAL INCPriority: Mar 15, 2000Filed: Aug 21, 2015Published: Dec 10, 2015
Est. expiryMar 15, 2020(expired)· nominal 20-yr term from priority
Inventors:Michael KutrykRobert J. CottoneStephen Rowland
A61L 31/148A61L 27/303A61P 9/10A61L 31/125A61L 29/103A61K 38/363A61L 31/084A61L 2300/416A61K 39/39558A61L 31/16C12N 5/0692A61F 2/2412A61L 2300/606A61L 29/126A61K 38/39A61L 29/16A61L 2300/422B82Y 30/00A61L 31/10C07K 2317/55A61L 31/047A61L 27/08A61L 27/44C07K 16/2896A61L 2300/432C12N 2510/00A61L 27/54A61L 27/227A61L 2420/04A61L 2300/256A61L 31/022A61F 2/82A61F 2/07
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a method for healing blood vessels by stimulating the formation of a confluent endothelial autologous cell layer in vivo on an implantable metallic stent having a lumen and a luminal surface, and an exterior surface. More specifically, the method includes implanting the stent with a coating in a patient in need of thereof; wherein the coating includes one or more layers of a matrix covalently adherent on said luminal and exterior surface of said stent containing one or more pharmaceutical substances on said exterior surface and a therapeutically effective amount of a single type of antibody, antibody fragments or combinations thereof being compatible to binding selectively to a specific cell surface antigen of circulating autologous endothelial progenitor cells in peripheral blood. In addition, genetically engineered endothelial progenitor cells can be captured on said luminal surface of stent in vivo, to proliferate to form rapidly a confluent endothelium in situ.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An artificial heart valve having a coating, wherein the coating comprises a matrix, the matrix comprising a plurality of antibodies, antibody fragments or combinations thereof and wherein the plurality of antibodies, antibody fragments or combinations thereof specifically bind to a cell surface antigen of endothelial progenitor cells or endothelial cells. 
     
     
         2 . The artificial, heart valve of  claim 1 , wherein the cell surface antigen is CD34, CD45, CD31, Flk-1, Tie-2 or E-selectin. 
     
     
         3 . The artificial heart valve of  claim 1 , wherein the plurality of antibodies, antibody fragments or combinations thereof are immobilized to the matrix. 
     
     
         4 . The artificial heart valve of  claim 1 , wherein the plurality of antibodies, antibody fragments or combinations thereof are covalently attached to the matrix. 
     
     
         5 . The artificial heart valve of  claim 1 , wherein the plurality of antibodies, antibody fragments or combinations thereof are monoclonal. 
     
     
         6 . The artificial heart valve of  claim 1 , wherein the plurality of antibodies, antibody fragments or combinations thereof are polyclonal. 
     
     
         7 . The artificial heart valve of  claim 1 , wherein the matrix comprises a plurality of Fab or F(ab′) 2  fragments. 
     
     
         8 . The artificial heart valve of  claim 1 , wherein the plurality of antibodies, antibody fragments or combinations thereof specifically bind to different cell surface antigens. 
     
     
         9 . The artificial heart valve of  claim 1 , wherein the plurality of antibodies, antibody fragments or combinations thereof capture endothelial progenitor cells and/or endothelial cells in vivo when the artificial heart valve is implanted into a subject. 
     
     
         10 . The artificial heart valve of  claim 1 , wherein the matrix comprises a polymer. 
     
     
         11 . The artificial heart valve of  claim 10 , wherein the polymer is bioabsorbable. 
     
     
         12 . The artificial heart valve of  claim 10 , wherein the polymer is synthetic. 
     
     
         13 . The artificial heart valve of  claim 12 , wherein the synthetic polymer is polyurethane, segmented polyurethane-urea/heparin, poly-lactic acid, cellulose ester, polyethylene glycol, polytetrafluoroethylene, expanded polytetrafluoroethylene, or combinations thereof. 
     
     
         14 . The artificial heart valve of  claim 10 , wherein the polymer is natural. 
     
     
         15 . The artificial heart valve of  claim 14 , wherein, the natural polymer is collagen, laminin, heparin, fibrin, cellulose, elastin, or combinations thereof. 
     
     
         16 . A venous valve having a coating, wherein the coating comprises a matrix, the matrix comprising a plurality of antibodies, antibody fragments or combinations thereof and wherein the plurality of antibodies, antibody fragments or combinations thereof specifically bind to a cell surface antigen of endothelial progenitor cells or endothelial cells. 
     
     
         17 . The venous valve of  claim 16 , wherein the cell surface antigen is CD34, CD45, CD31, Flk-1, Tie-2 or E-selectin. 
     
     
         18 . The venous valve of  claim 16 , wherein the plurality of antibodies, antibody fragments or combinations thereof are immobilized to the matrix. 
     
     
         19 . The venous valve of  claim 16 , wherein the plurality of antibodies, antibody fragments or combinations thereof are monoclonal. 
     
     
         20 . The venous valve of  claim 1 , wherein the matrix comprises a polymer.

Join the waitlist — get patent alerts

Track US2015352263A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.